| Stereochemistry | RACEMIC |
| Molecular Formula | C20H23NO.ClH |
| Molecular Weight | 329.864 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC(C1CN2CCC1CC2)(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=MVCBFPDJWSQMNY-UHFFFAOYSA-N
InChI=1S/C20H23NO.ClH/c22-20(17-7-3-1-4-8-17,18-9-5-2-6-10-18)19-15-21-13-11-16(19)12-14-21;/h1-10,16,19,22H,11-15H2;1H
| Molecular Formula | C20H23NO |
| Molecular Weight | 293.4027 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Quifenadine is an antihistaminic agent.
Quifenadine both blocks histamine H1-receptors in the peripheral tissues, and activates enzyme diaminoxidase (histaminase), due to this decreasing the histamine concentration in tissues.
It is indicated in cases of pollinosis, acute and chronic urticaria, seasonal rhinitis (hay fever), allergic rhinitis, allergic conjunctivitis, angioneurotic Quinqe’s edema, dermatosis (eczema, neurodermatitis, pruritus etc.), allergic reactions caused by food or medicines. Quifanidine exhibits antiarrhythmic activity in children with frequent premature beats, without significant QT prolongation, or sinus node depression.
Approval Year
Patents
Sample Use Guides
For adults: single dose is 25-50 mg 2-4 times a day. Maximum daily dose is 200 mg.
For children older than 12 years - 25 mg 2-3 times a day.
The duration of the course of treatment is 10-20 days. If it is necessary, the course of treatment may be repeated.
Route of Administration:
Oral
